Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics, Philips to Collaborate on MDx Platform

NEW YORK (GenomeWeb News) – Epigenomics today said that it has signed a collaboration and licensing agreement with Royal Philips Electronics to develop a molecular diagnostics platform for running cancer tests.
 
The firms will jointly perform feasibility studies aimed at developing a fully automated instrument platform for diagnosing certain cancers based on DNA methylation biomarkers.
 
As part of the pact, Philips obtained the option to license the technologies and biomarkers separately or in combination for diagnostic applications. The Dutch electronics and medical imaging equipment firm may exercise the option upon successful completion of the feasibility studies, said Epigenomics.
 
Financial details of the agreement were not disclosed.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.